🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs
7,238

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Page 115 of 151

  1. SPD602

    Takeda

    Transfusional Iron Overload

    phase 2 small molecule terminated

    2 trials

  2. SPD602 (FBS0701, SSP-004184)

    Takeda

    Transfusional Iron Overload

    phase 2 small molecule completed

    1 trial

  3. SPGL008

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    NMIBC

    phase 2 mab active

    1 trial

  4. SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

    Lacuna Pharma Pty Ltd

    Hypercortisolism related to benign adrenal tumour

    phase 2 other active

    1 trial

  5. SPI-62_DF2

    Lacuna Pharma Pty Ltd

    Cushing's Syndrome

    phase 2 small molecule active

    1 trial

  6. SPINALON (buspirone + levodopa + cardidopa)

    United Therapeutics Europe Ltd

    Spinal Cord Injury

    phase 2 small molecule completed

    1 trial

  7. SPM 962

    Otsuka Beijing Research Institute

    Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  8. SPN-810

    SUPERNUS PHARMACEUTICALS, INC.

    Impulsive Aggression Comorbid With ADHD

    phase 2 small molecule completed

    1 trial

  9. SPN-810

    SUPERNUS PHARMACEUTICALS, INC.

    Attention Deficit Disorder With Hyperactivity

    phase 2 small molecule completed

    1 trial

  10. SPN-817

    SUPERNUS PHARMACEUTICALS, INC.

    Epilepsy

    phase 2 small molecule active

    1 trial

  11. SPN-817

    SUPERNUS PHARMACEUTICALS, INC.

    Focal Onset Seizures

    phase 2 small molecule active

    2 trials

  12. SPN-821 2400 mg

    SUPERNUS PHARMACEUTICALS, INC.

    Major Depressive Disorder (MDD)

    phase 2 small molecule active

    1 trial

  13. SPR001

    SPRUCE BIOSCIENCES, INC.

    Congenital Adrenal Hyperplasia

    phase 2 small molecule completed

    2 trials

  14. SPR720

    Spero Therapeutics

    Mycobacterium Avium Complex

    phase 2 small molecule terminated

    1 trial

  15. SPRYCEL 70 mg film-coated tablets, Venetoclax, SPRYCEL 100 mg film-coated tablets, Venetoclax, SPRYCEL 20 mg film-coated tablets, Venetoclax, SPRYCEL 50 mg film-coated tablets, Venetoclax, Venetoclax, Venetoclax, SPRYCEL 10 mg/mL powder for oral suspension

    AXIM BIOTECHNOLOGIES, INC.

    Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

    phase 2 small molecule active

    1 trial

  16. SPT-300

    Seaport Therapeutics

    Major Depressive Disorder (MDD)

    phase 2 small molecule active

    2 trials

  17. SPY001

    Spyre Therapeutics

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  18. SPY002-072

    Spyre Therapeutics

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  19. SPYPBO-101 Placebo to SPY072, SPY072

    Spyre Therapeutics

    Moderately to Severely Active Rheumatologic Disease

    phase 2 small molecule active

    1 trial

  20. SPYPBO-102, SPYPBO-101, SPY002, SPY002, SPY001-001, SPY001-001

    Spyre Therapeutics

    Moderately to Severely Active Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  21. SR-T100 ® Gel

    Biotech Pharmaceutical Co.,

    Actinic Keratosis

    phase 2 small molecule completed

    1 trial

  22. SR419

    Shanghai University of Traditional Chinese Medicine

    Peripheral Neuropathic Pain

    phase 2 small molecule completed

    1 trial

  23. SRF388

    Coherus Oncology

    Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  24. SRF617

    Arcus Biosciences

    Metastatic Castration-resistant Prostate Cancer

    phase 2 small molecule terminated

    1 trial

  25. SRM003

    Takeda

    Arteriovenous Graft

    phase 2 mab terminated

    1 trial

  26. SRM003

    Takeda

    Arteriovenous Fistula

    phase 2 mab completed

    1 trial

  27. SRP-5051

    Sarepta Therapeutics

    Muscular Dystrophy, Duchenne

    phase 2 small molecule terminated

    2 trials

  28. SRP-9003

    Sarepta Therapeutics

    Limb-Girdle Muscular Dystrophy, Type 2E

    phase 2 gene therapy terminated

    1 trial

  29. SRP-9004

    Sarepta Therapeutics

    Limb-Girdle Muscular Dystrophy, Type 2D

    phase 2 gene therapy completed

    1 trial

  30. SRX246

    United Therapeutics Europe Ltd

    PTSD

    phase 2 small molecule terminated

    1 trial

  31. SS-1

    Hospital Authority, Hong Kong

    Sjögren's Syndrome

    phase 2 small molecule active

    1 trial

  32. SS-1

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Sjögren's Syndrome

    phase 2 small molecule active

    1 trial

  33. SSGJ-705

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Locally Advanced, Recurrent or Metastatic Malignancies

    phase 2 small molecule active

    2 trials

  34. SSGJ-706

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    First-line Advanced NSCLC Patients

    phase 2 small molecule active

    1 trial

  35. SSGJ-706+XELOX

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Gastric/Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  36. SSGJ-707

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    NSCLC

    phase 2 small molecule active

    1 trial

  37. SSGJ-707

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  38. SSGJ-707

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    First-line Advanced NSCLC Patients

    phase 2 small molecule active

    1 trial

  39. SSGJ-707

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer

    phase 2 small molecule active

    1 trial

  40. SSP-002358 (0.1 mg) + PPI

    Takeda

    Gastroesophageal Reflux Disease

    phase 2 small molecule completed

    1 trial

  41. SSP-004184AQ

    Takeda

    Iron Overload Due to Repeated Red Blood Cell Transfusions

    phase 2 small molecule terminated

    1 trial

  42. SSS06

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Chemotherapy-induced Anemia

    phase 2 small molecule active

    1 trial

  43. SSS17

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Anemia in Pre-Dialysis Patients

    phase 2 small molecule completed

    1 trial

  44. SSS17 Capsule (6 Dose Levels)

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Postoperative Anemia

    phase 2 small molecule active

    1 trial

  45. ST-400 Investigational product

    SANGAMO THERAPEUTICS, INC

    Transfusion Dependent Beta-thalassemia

    phase 2 gene therapy completed

    1 trial

  46. ST-503

    SANGAMO THERAPEUTICS, INC

    Chronic Neuropathic Pain

    phase 2 gene therapy active

    1 trial

  47. ST-920

    SANGAMO THERAPEUTICS, INC

    Fabry Disease (X-linked lysosomal storage disease).

    phase 2 small molecule active

    1 trial

  48. ST-920

    SANGAMO THERAPEUTICS, INC

    Fabry Disease

    phase 2 mab completed

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.